Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AZD9829 targets hard-to-treat blood cancers in early trial

NCT ID NCT06179511

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a new drug, AZD9829, in people with blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD123 found on cancer cells. The main goals are to find a safe dose and check for side effects. About 56 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

56 people

The number who actually took part.

Started

Jan 2024

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age; * CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory; * R/R AML (except APL); * R/R HR-MDS with ≥5% bone marrow blast at time of inclusion; * Had at least 1 prior line of therapy at currents histology, and have no available treatment options; * ECOG performance status of ≤ 2. The above is a summary, other inclusion criteria details may apply. Exclusion Criteria: * Active CNS leukemia; * Previous treatment with any CD123 targeting therapy; * Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy; * Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829; * History of other malignancy(with certain exceptions); * Active and uncontrolled infections; * Unresolved AEs ≥2 Grade, from prior therapies. The above is a summary, other exclusion criteria details may apply .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological malignancies

Contacts and locations

Locations

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    New York, New York, 10021, United States

  • Research Site

    Chapel Hill, North Carolina, 27514, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

  • Research Site

    Heidelberg, 3084, Australia

  • Research Site

    Melbourne, VIC 3000, Australia

  • Research Site

    Tianjin, 300020, China

  • Research Site

    Frankfurt, 60590, Germany

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Osaka, 545-8586, Japan

  • Research Site

    Yoshida-gun, 910-1193, Japan

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Manchester, M204BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.